360 documents

Read All
20:29 , Jul 16, 2019 |  BC Extra  |  Financial News

July 16 Financial Quick Takes: J&J growth drivers beat consensus; plus Notable and Cradle raise funds

Imbruvica, Darzalex sales top analysts' consensus  In its 2Q19 earnings report, Johnson & Johnson (NYSE:JNJ) said revenue from its pharmaceutical segment grew to $10.53 billion during the quarter, up 1.7% compared with 2Q18, with newer...
Read More
22:56 , Jun 28, 2019 |  BC Extra  |  Company News

CHMP knocks Evenity for osteoporosis, backs Giapreza for hypotension

EMA's CHMP issued a basket of opinions Friday, including a negative opinion for Amgen's osteoporosis drug Evenity, and a recommendation for La Jolla's hypotension therapy Giapreza. The agency recommended against approval of Evenity romosozumab-aqqg from...
Read More
01:10 , Jun 26, 2019 |  BioCentury  |  Product Development

AbbVie chooses revenue over innovation with Allergan takeout

Six years after splitting from Abbott to pursue innovative drug development, AbbVie has taken a clear about-face, choosing a certain immediate revenue stream in its proposed acquisition of Allergan rather than opting for a riskier,...
Read More
14:20 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

The OXPHOS complex I inhibitor IACS-010759 for mantle cell and B cell lymphoma

DISEASE CATEGORY: Cancer INDICATION: Mantle cell lymphoma (MCL); B cell lymphoma Patient sample, cell culture and mouse studies identified an OXPHOS complex I inhibitor that could help treat MCL and B cell lymphoma that are...
Read More
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
Read More
23:51 , Mar 14, 2019 |  BC Week In Review  |  Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
Read More
01:33 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

FDA approves first chemotherapy-free combo for CLL. SLL

AbbVie Inc. (NYSE:ABBV) and partner Johnson & Johnson (NYSE:JNJ) said FDA approved an sNDA for Imbruvica ibrutinib plus Gazyva obinutuzumab for treatment-naïve adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The regimen is the...
Read More
20:56 , Jan 28, 2019 |  BC Extra  |  Company News

FDA approves first chemotherapy-free combo for CLL, SLL

AbbVie Inc. (NYSE:ABBV) and partner Johnson & Johnson (NYSE:JNJ) said FDA approved an sNDA for Imbruvica ibrutinib plus Gazyva obinutuzumab for treatment-naïve adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The regimen is the...
Read More
17:12 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib missed the co-primary endpoints in the double=blind, international Phase III RESOLVE (PCYC-1137) trial as part of a first-line combination treatment of metastatic pancreatic cancer. In 424 patients, Imbruvica plus...
Read More
23:39 , Jan 18, 2019 |  BC Extra  |  Clinical News

AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said late Friday Imbruvica ibrutinib missed the co-primary endpoints in the Phase III RESOLVE (PCYC-1137) trial as part of a first-line combination treatment of metastatic pancreatic cancer. In 424 patients, the Bruton's...
Read More